Bullish
The FDA has selected seven pharmaceutical companies, including Eli Lilly and Regeneron, for its PreCheck Pilot Program. This initiative aims to expedi...
Bullish
The FDA has chosen Eli Lilly and Regeneron, along with five other companies, for its PreCheck pilot program. This initiative aims to accelerate the re...
Neutral
Regeneron Pharmaceuticals, Inc. (REGN) is being considered among the top AI-powered healthcare stocks by hedge funds after the FDA and European Medici...
Neutral
RBC Capital has maintained a Sector Perform rating on Regeneron Pharmaceuticals (NASDAQ: REGN) with a $707 price target, though it views AbbVie's acqu...
Neutral
Leading pharmaceutical companies are spending billions on immunology assets, often paying significant premiums, to secure late-stage biologics. This s...
Regeneron Pharmaceuticals recently received Priority Review from the FDA for cemdisiran to treat generalized myasthenia gravis (gMG), with a target ac...
Neutral
Regeneron Pharmaceuticals, Inc. announced it will release its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before t...
Bullish
Prominent construction companies with offices in the Capital Region are involved in Regeneron's $2 billion expansion project in Saratoga Springs. Rege...
Neutral
Regeneron Pharmaceuticals announced that the FDA and European Medicines Agency (EMA) have accepted regulatory applications for cemdisiran to treat gen...
Neutral
Regeneron's marketing applications for cemdisiran, an experimental therapy for myasthenia gravis developed with Alnylam Pharmaceuticals, have been acc...
Regeneron Pharmaceuticals, Inc. published a slide deck in conjunction with a shareholder/analyst call. The article, released by SA Transcripts, highli...
Bullish
This article summarizes a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN), arguing that the market mischaracterizes it as a one-product compa...
Bearish
The Schall Law Firm is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for potential securities law violations after a Phase 3 trial for ...
Bullish
Parabilis Medicines (PBLS) saw a significant surge of over 45% on its first day of trading. The biotechnology company, specializing in cancer drug dev...
Bullish
Parabilis Medicines successfully raised $670 million in an above-range initial public offering, selling 33.5 million shares at $20 each. The company a...
Neutral
Regeneron Pharmaceuticals (REGN) has received support from the World Health Organization (WHO) for its antibody therapy, maftivimab, to be evaluated i...
Bullish
Parabilis Medicines, a Cambridge-based cancer-focused biotech company, is planning a $450 million IPO with backing from Regeneron. The company has alr...
Neutral
Parabilis Medicines (PBLS), a cancer drug developer with a research collaboration with Regeneron (REGN), is aiming to raise up to $476 million in its ...
Bullish
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is set to present clinical data at the American Diabetes Association 86th Scientific Sessions and the En...
Bullish
Regeneron has expanded its collaboration with CytomX Therapeutics, increasing potential payments by up to $2 billion and adding eight more targets for...